OpenNashEarnings

Medical Devices · Nasdaq: GEHC

GE HealthCare earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 3 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

GE HealthCare agreed to buy SOFIE Biosciences, adding final-mile PET radiopharmaceutical supply to its drug-plus-imaging strategy as new imaging platforms clear regulatory milestones.

GE HealthCare's growth came from Advanced Imaging Solutions and Pharmaceutical Diagnostics, with orders still healthy and a backlog of $23.7 billion. It won CE marking for the Photonova Spectra photon-counting CT, has StarGuide GX SPECT/CT pending with the FDA, and launched new ultrasound products. Contrast media and radiopharmaceuticals drove Pharmaceutical Diagnostics. Patient Care Solutions recovered as supply and fulfillment improved under the company's Heartbeat operating system.

Read the Q3 2026 summary →

Quarters

KPI history

Revenue$5.5B+7.2% y/yQ3 2026
Q4 2024: $5.3B (worked out from the annual figure)Q4 ’24$5.3BQ1 2025: $4.8BQ1 ’25$4.8BQ2 2025: $5.0BQ2 ’25$5.0BQ3 2025: $5.1BQ3 ’25$5.1BQ4 2025: $5.7B (worked out from the annual figure)Q4 ’25$5.7BQ1 2026: $5.1BQ1 ’26$5.1BQ2 2026: $5.3BQ2 ’26$5.3BQ3 2026: $5.5BQ3 ’26$5.5B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$5.3B *
Q1 2025$4.8B
Q2 2025$5.0B
Q3 2025$5.1B
Q4 2025$5.7B *
Q1 2026$5.1B
Q2 2026$5.3B
Q3 2026$5.5B
Diluted EPS (GAAP)$1.36+38.8% y/yQ3 2026
Q1 2025: $1.23Q1 ’25$1.23Q2 2025: $1.06Q2 ’25$1.06Q3 2025: $0.98Q3 ’25$0.98Q1 2026: $0.85Q1 ’26$0.85Q2 2026: $1.24Q2 ’26$1.24Q3 2026: $1.36Q3 ’26$1.36
Data
Q1 2025$1.23
Q2 2025$1.06
Q3 2025$0.98
Q1 2026$0.85
Q2 2026$1.24
Q3 2026$1.36

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin14.6%+1.9 pts y/yQ3 2026
Q4 2024: 15.1%Q4 ’2415.1%Q1 2025: 13.2%Q1 ’2513.2%Q2 2025: 13.1%Q2 ’2513.1%Q3 2025: 12.7%Q3 ’2512.7%Q4 2025: 14.5%Q4 ’2514.5%Q1 2026: 10.0%Q1 ’2610.0%Q2 2026: 14.0%Q2 ’2614.0%Q3 2026: 14.6%Q3 ’2614.6%
Data
Q4 202415.1%
Q1 202513.2%
Q2 202513.1%
Q3 202512.7%
Q4 202514.5%
Q1 202610.0%
Q2 202614.0%
Q3 202614.6%
Free cash flow$793.0M+64.2% y/yQ3 2026
Q1 2025: $98.0MQ1 ’25$98.0MQ2 2025: $8.0MQ2 ’25$8.0MQ3 2025: $483.0MQ3 ’25$483.0MQ1 2026: $112.0MQ1 ’26$112.0MQ2 2026: $68.0MQ2 ’26$68.0MQ3 2026: $793.0MQ3 ’26$793.0M
Data
Q1 2025$98.0M
Q2 2025$8.0M
Q3 2025$483.0M
Q1 2026$112.0M
Q2 2026$68.0M
Q3 2026$793.0M

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$5.3Bd$4.8B$5.0B$5.1B$5.7Bd$5.1B$5.3B$5.5B
Gross margin42.8%42.1%39.6%38.7%39.7%38.5%41.2%40.3%
Operating income$801.0Md$629.0M$654.0M$653.0M$827.0Md$515.0M$739.0M$805.0M
Operating margin15.1%13.2%13.1%12.7%14.5%10.0%14.0%14.6%
Net income$721.0Md$564.0M$486.0M$446.0M$589.0Md$389.0M$561.0M$615.0M
Diluted EPS—$1.23$1.06$0.98—$0.85$1.24$1.36
Operating cash flow—$250.0M$94.0Md$593.0Md—$290.0M$168.0Md$907.0Md
Capital expenditure$102.0Md$152.0M$86.0Md$110.0Md$134.0Md$178.0M$100.0Md$114.0Md
Free cash flow—$98.0M$8.0M$483.0M—$112.0M$68.0M$793.0M
R&D expense$344.0Md$344.0M$302.0M$292.0M$323.0Md$345.0M$323.0M$320.0M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings